We're currently looking for a Senior Statistician/Principal Statistician to join our team. You can find out more, including how to apply, here: jobs.icr.ac.uk/vacancies/14... 🧪

Senior Statistician / Principal Statistician in Sutton | The Institute of Cancer Research

View details and apply for this Senior Statistician / Principal Statistician vacancy in Sutton. Salary : Senior Statistician: £47,634 - £52,324 Principal Statistician: £49,9...

jobs.icr.ac.uk

We were @estroradiotherapy.bsky.social #ESTRO2026 last weekend, where @profemmahall.bsky.social received an honorary member award.

The 10 year results of our Fast-Forward trial of breast cancer radiotherapy have just been published. Thanks to all our trial participants and colleagues at NHS sites across the UK who contributed, helping us to confirm that one week radiotherapy is as safe and effective as a three week course. 🧪

The Institute of Cancer Research@icr.ac.uk · 5mo ago

🚨 New results published recently in @thelancetoncol.bsky.social show one-week radiotherapy is as safe and effective as the traditional three-week course for early-stage breast cancer.

Today is International Clinical Trials Day, recognising the vital role of research to improve healthcare. We are grateful to all of our trial participants, NHS colleagues and scientific partners for helping us translate cutting-edge science into trials that transform cancer care. #ICTD2026

Are you attending the annual @estroradiotherapy.bsky.social congress this weekend? Researchers are presenting 8 different trials managed by the ICR’s Clinical Trials and Statistics Unit. ICR's Professor @profemmahall.bsky.social shares her thoughts ahead of the event ⬇️ #ESTRO26

If you are at #ESTRO2026 this weekend, don't miss the Designing radiotherapy trials for the future generation session on Sunday morning, where our Director, @profemmahall.bsky.social, will be speaking on lessons learned in over two decades of trial design.

We are looking forward to #ESTRO2026 this weekend, where results of our trials investigating radiotherapy in breast cancer, prostate cancer and head and neck cancer will be presented. @estroradiotherapy.bsky.social

A new trial design framework for incorporating patient-reported outcomes into dose-optimisation trials "PRO-ADD (Patient-Reported Outcomes Aided Dose-optimisation Design)" is now published in Statistical Methods in Medical Research: journals.sagepub.com/doi/full/10....

PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selection - Emily Alger, Sumithra J Mandrekar, Jun Yin, Christina...

Advances in oncology drug development are driving the emergence of novel therapies, challenging traditional dose-efficacy assumptions in dose-finding oncology t...

journals.sagepub.com

We're currently looking for a Research Administrator to join our team. You can find out more about the role, including how to apply, here: jobs.icr.ac.uk/vacancies/14...

Research Administrator in Sutton | The Institute of Cancer Research

View details and apply for this Research Administrator vacancy in Sutton. Salary: £26,505- £30,690 per annum FTE Duration of Contract : Fixed Term for 12 months Hours...

jobs.icr.ac.uk

Marking this #EarthDay as part of the fantastic TMRP Greener Trials Group. It's a privilege to work with such brilliant collaborators, focused on how to make clinical trials #Greener. Details of how to join or contribute to this work are below @mrchrisaddison.bsky.social @icr-ctsu.bsky.social

MRC-NIHR Trials Methodology Research Partnership@mrcnihrtmrp.bsky.social · 6mo ago

🌍 International Earth Day 🌍 Clinical research doesn’t sit outside healthcare - it’s embedded within it. Clinical trials are essential for improving health, but they also have a carbon footprint. 🧵⬇️ @lisa-fox.bsky.social

The first publication from the KORTUC phase II trial has been published: www.sciencedirect.com/science/arti... 🧪

Modification of RECIST 1.1 criteria for assessing response in breast tumours treated with radiation therapy using multiparametric breast MRI: Radiology and oncology perspective

The traditional, size-based, RECIST 1.1 guideline is the standard for assessing tumour response, but has notable limitations, particularly for breast …

sciencedirect.com

The OPTIMISE‑AR paper was published in @thelancetoncol.bsky.social last week. This introduces a practical toolkit to support the analysis and visualisation of patient‑reported outcomes (PROs) in early‑phase dose‑finding oncology trials. 🧪

Results of the TORPEdO trial (Proton beam therapy for oropharyngeal cancer), the UK's first #ProtonBeam trial, have been published in @thelancet.com. You can read the full paper here: authors.elsevier.com/sd/article/S... 🧪

We recently published a paper about developing a demographic question set for research participants. We worked with patients and members of the public to agree an acceptable set of questions we can ask our participants. link.springer.com/article/10.1...

Establishing a set of acceptable demographic questions for use in health research through public consultation - Research Involvement and Engagement

Background The importance of inclusivity in health care and health research is increasingly recognised in the UK. However, there are currently no UK standards for collecting self-reported demographic ...

link.springer.com

Our former director, Professor Judith Bliss, will be speaking at this webinar on 17th March to celebrate International Women's Day #IWD2026 See below for details on how to register.

UK CTU Network@ukctunetwork.org · 7mo ago

Registration has opened for our webinar 'Women at the helm: reflections on leadership, over changing times' featuring the inspirational Julia Brown & Judith Bliss! 📆 17 March 2026 ⏰ 12:00 Please contact the #UKCTUNetwork Secretariat for details on how to register. #IWD2026

Could expanding SBRT to pelvic lymph nodes improve outcomes for men with high-risk #ProstateCancer? @profemmahall.bsky.social and Dr Angela Pathmanathan @icr.ac.uk, funded by Prostate Cancer UK, detail their trial approach in ctRO. Grab a ☕ and read: www.ctro.science/article/S240...

Tomorrow, members of our #sustainability working group will be presenting as part of this seminar on the #EnvironmentalImpact of #ClinicalTrials. 🧪

NIHR Research Support Service (RSS)@nihr-rss.bsky.social · 8mo ago

Upcoming RSS Webinar: Environmental Impact of Clinical Trials 🗓 4 March, 12 -1pm The session will cover ways to calculate the carbon footprint of trials and initiatives in this area aimed to help improve the design and running of trials. Join the webinar: teams.microsoft.com/meet/3338503...

Last week Dr Anna Wilkins presented "External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker in the randomised phase III CHHiP trial" at the GU-ASCO conference.

The PACE-NODES protocol paper has been published in Clinical and Translational Radiation Oncology. The #ClinicalTrial is comparing treating localised #ProstateCancer patients with SBRT over 5 days to the prostate alone or both the prostate and pelvis. www.sciencedirect.com/science/arti...

PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT

PACE-NODES is a phase III randomised controlled trial for patients with high risk localised prostate cancer, planned for radical radiotherapy with at …

sciencedirect.com

We are looking for a new Data Curator/Engineer. For more information on the role and how to apply, follow the link below. #ResearchJobs 🧪 jobs.icr.ac.uk/vacancies/14...

Data Curator/Engineer in Sutton | The Institute of Cancer Research

View details and apply for this Data Curator/Engineer vacancy in Sutton. Salary : Salary range £39,805 - £41,900 per annum. Commencement on the salary range is subject to comparable skills a...

jobs.icr.ac.uk

It was an honour to represent @icr-ctsu.bsky.social at this event. Our collaboration with the ICR’s Division of Radiotherapy & Imaging has been a cornerstone of our trials portfolio for many years and we are proud of our contribution to the radiotherapy research recognised through this award.

The Institute of Cancer Research@icr.ac.uk · 8mo ago

✨🏆Today, His Majesty The King honoured the ICR with the Queen Elizabeth Prize for Higher and Further Education. We're so proud to be recognised for our sustained, world-leading contributions to radiotherapy research and education. Read more about our big day here ⤵️ www.icr.ac.uk/about-us/icr...

Last week, the FAST-Forward Boost trial completed recruitment to the Early Side Effects Substudy with 345 patients randomised. The study will now be transitioning to the main trial part of the study with a target of 4,830 patients. You can read more about the trial here: www.icr.ac.uk/ff-boost

Today is #WorldCancerDay. This week we’re highlighting impactful work from Registered CTUs. The @icr-ctsu.bsky.social IMPORT HIGH trial showed that treatment times for radiotherapy could be reduced for some early breast cancer patients. 🔗 tinyurl.com/y76mwfj8 #UKCTUNetwork #UnitedByUnique

4 February is #WorldCancerDay. This week we’re highlighting impactful work from Registered CTUs, starting with this ICR-CTSU project setting out recommendations for patient‑reported outcomes in early cancer drug trials: tinyurl.com/35p76f3u #UKCTUNetwork #UnitedByUnique @icr-ctsu.bsky.social

Study sets out clear recommendations for patient-reported outcomes in early cancer drug trials

Study sets out clear recommendations for patient-reported outcomes in early cancer drug trials

tinyurl.com

New research introduces the first practical guidance on how patients’ own assessments of how tolerable they find treatments (patient-reported outcomes) can be used more effectively to inform and design early-stage cancer drug trials. A thread 🧵⬇️

📢 We are doing a study called INTERACT to find out whether any groups of people have been less likely to take part in cancer studies in the UK. We'll use routine data collected by NHS England to see if there are any differences between those who joined our clinical trials and those who did not.

Delighted to share OPTIMISE-ROR – recommendations to help embed patient-reported outcomes (PROs) more meaningfully in dose-finding oncology trials. It sets out core PRO objectives to support tolerability assessment, dose selection, and PRO strategy for subsequent studies. tinyurl.com/45thervu.

International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR - PubMed

This foundational guidance outlines key PRO research objectives in DFOTs. By facilitating the systematic integration of PROs, this guidance supports the utilization of patient-centered evidence for the tolerability and efficacy assessment of therapies to inform dose escalation, optimization, and reg …

tinyurl.com

Proud to have contributed to this paper, looking at real world evidence on the efficacy and safety of pembrolizumab in patients with early triple negative #BreastCancer www.sciencedirect.com/science/arti...

UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer

The KEYNOTE-522 trial showed that use of pembrolizumab-chemotherapy for stage 2-3 triple-negative breast cancer improved pathological complete respons…

sciencedirect.com

We are looking forward to attending UKIBCS this morning and learning about recent advances in #BreastCancer 🧪

We're looking for people with experience of cancer who would like to share their thoughts and opinions with us to help design and deliver research at the ICR. If you interested in helping research at the ICR, please fill out the registration form. forms.office.com/e/YQ0SbaJ1ix 🧪 #Research